{
  "id": 1932415,
  "title": "U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome",
  "url": "https://urgent.news/2026/08/19/u-s-fda-accepts-tevas-new-drug-application-nda-and-grants-priority",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-19T12:33:46.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/u-s-fda-accepts-tevas-new-drug-application-nda-and-grants-priority-review-for-ecopipam-a-first-in-class-investigational-therapy-for-pediatric-patients-with-tourette-syndrome"
  },
  "original_language": "en",
  "account": null,
  "summary": "Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation NDA acceptance is supported by positive Phase 3 data, which were published in JAMA Neurology, and Phase 2b data If approved, ecopipam would be the first new treatment option indicated for pediatric patients with Tourette syndrome in more than 10 years and […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "Teva gets FDA priority review for Tourette syndrome therapy",
        "url": "https://urgent.news/2026/08/19/teva-gets-fda-priority-review-for-tourette-syndrome-therapy",
        "published": "2026-08-19T12:54:08.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}